Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab

• Senoo Satoru

  Department of Respiratory Medicine, Okayama University Hospital, Japan

• Ninomiya Takashi

  Department of Respiratory Medicine, Okayama University Hospital, Japan

• Makimoto Go

  Department of Respiratory Medicine, Okayama University Hospital, Japan

• Nishii Kazuya

  Department of Respiratory Medicine, Okayama University Hospital, Japan

• Kano Hirohisa

  Department of Respiratory Medicine, Okayama University Hospital, Japan

• Watanabe Hiromi

  Department of Respiratory Medicine, Okayama University Hospital, Japan

• Hata Yusuke

  Department of Respiratory Medicine, Okayama University Hospital, Japan Department of Respiratory Medicine, Kure Kyosai Hospital, Japan

• Kubo Toshio

  Department of Respiratory Medicine, Okayama University Hospital, Japan

• Tanaka Takehiro

  Division of Diagnostic Pathology, Okayama University Hospital, Japan

• Hotta Katsuyuki

  Center for Innovative Clinical Medicine, Okayama University Hospital, Japan

• Maeda Yoshinobu

  Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan

• Kiura Katsuyuki

  Department of Respiratory Medicine, Okayama University Hospital, Japan

Abstract

Pulmonary pleomorphic carcinoma (PPC) is a rare very aggressive subtype of non-small cell lung cancer. We herein report a case of PPC that showed a rapid response to nivolumab. The patient, whose multiple tumors had progressed very aggressively, was treated with nivolumab, an anti-programmed cell death-1 (PD-1) antibody. The tumors dramatically shrank after one cycle of nivolumab. The tumors were positive for programmed cell death ligand 1 (PD-L1). An immunohistochemical analysis revealed numerous PD-1⁺, CD68⁺ and CD206⁺ macrophages. This PD-1 antibody may be a good treatment option, especially in tumors that express PD-L1 and which show PD-1⁺ macrophage infiltration.

Journal

• Internal Medicine

  Internal Medicine 58 (7), 985-989, 2019-04-01

  The Japanese Society of Internal Medicine

Keywords

• pulmonary pleomorphic carcinoma
• immune checkpoint inhibitor
• PD-1
• PD-L1
• FGFR

Details

• CRID: 1390845713072459648
• NII Article ID: 130007622179
• DOI: 10.2169/internalmedicine.0890-18
• ISSN: 13497235
• ISSN: 09182918
• PubMed: 30568113
• Web Site: https://www.jstage.jst.go.jp/article/internalmedicine/58/7/58_0890-18/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2020074590
• Text Lang: en
• Data Source:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed